In patients with mCRC who harbor activating mutations of the mitogen-activated protein kinase (MAPK) pathway, research has shown the importance of recognizing that targeting a specific molecular alteration in this pathway can elicit different responses in patients with different tumor histologies; remarkably different outcomes were reported for patients with mCRC harboring BRAF V600 mutations compared with those with metastatic melanoma, and likewise for patients with mCRC harboring a KRAS G12C mutation compared with metastatic lung cancer [3,4]. Here, BRAF is linked to neoplasm.